# A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Source: https://onco.cc/trials/nct05862285/  
OnCo record `nct05862285` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Ipatasertib, now recruiting.

## Summary

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study is a phase 3 interventional study registered as NCT05862285, led by Hoffmann-La Roche, and recruiting on the registry. Official title: An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study. Planned enrolment is 100 participants (estimated). The study started in 2023-06-01 and primary completion is expected in 2033-03-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: UmbrellaMAX
- Tags: ctgov-ingest
- Registry id: NCT05862285
- Phase: 3
- Setting: An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
- Sponsor: Hoffmann-La Roche
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05862285: https://clinicaltrials.gov/study/NCT05862285

## Connected records

- drugs: [Ipatasertib](https://onco.cc/drugs/ipatasertib/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct05862285.json